Microcap Ledger Lifecore Biomedical, Inc. \de\ $LFCR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Chaska, MN
- Fiscal year end
- May 25
- Shares outstanding
- 37,853,060 [10-Q 2026-08-05]
What the company doesAI summary of filing
Lifecore Biomedical, Inc. is a contract development and manufacturing organization (CDMO) based in Minnesota that develops and manufactures complex sterile injectable pharmaceutical products. The company specializes in hyaluronic acid (HA) manufacturing using a proprietary fermentation process, as well as formulation and aseptic filling of HA-based and non-HA sterile injectables in syringes, vials, and cartridges across multiple therapeutic modalities including ophthalmic and orthopedic applications. Lifecore operates three cGMP-regulated facilities totaling 250,000 square feet and provides services spanning analytical method development, formulation development, process validation, clinical manufacturing, and commercial production for customers' injectable products. The company is revenue-generating, having divested its food businesses in May 2023 to operate as a standalone CDMO. [10-KT 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $57.36M | −$21.14M | $2.51M | $17.24M | [10-Q 2026-08-05] |
| FY ended May 2025 | $128.87M | −$38.70M | −$206.0K | $8.27M | [10-KT 2026-03-16] |
| FY ended May 2024 | $128.26M | $12.00M | $257.0K | $8.46M | [10-KT 2026-03-16] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-09-27 | 30,898,255 | [10-Q 2024-10-04] |
| 2024-12-26 | 37,025,331 | [10-Q 2025-01-02] |
| 2025-03-27 | 37,025,331 | [10-Q 2025-04-03] |
| 2025-07-31 | 37,407,919 | [10-K 2025-08-07] |
| 2025-10-30 | 37,466,352 | [10-Q 2025-11-06] |
| 2026-03-09 | 37,477,386 | [10-KT 2026-03-16] |
| 2026-04-29 | 37,509,407 | [10-Q 2026-05-06] |
| 2026-07-29 | 37,853,060 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2025-09-23; declared effective 2025-09-30 [S-3 2025-09-23]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-04 | Kiper Christopher S | grant | 25,907 | — | [4 2026-06-08] |
| 2026-06-04 | Obus Nelson | grant | 25,907 | — | [4 2026-06-05] |
| 2026-06-04 | Aryeh Jason | grant | 25,907 | — | [4 2026-06-05] |
| 2026-06-04 | Schechter Joshua | grant | 25,907 | — | [4 2026-06-05] |
| 2026-06-04 | Korenberg Matthew E | grant | 25,907 | — | [4 2026-06-05] |
| 2026-06-04 | Antunes Humberto Calheiros | grant | 25,907 | — | [4 2026-06-05] |
| 2026-06-04 | Johnson Paul Harold | grant | 25,907 | — | [4 2026-06-05] |
| 2026-06-04 | Houde Lovas Katrina | grant | 25,907 | — | [4 2026-06-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-29 | 8-K | Material agreement entered |
| 2026-09-28 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-28 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-07-29 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-02 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-02 | 8-K | Regulation FD disclosure |
| 2026-07-02 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-05 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-06 | 10-Q | Quarterly report |
Alerts for $LFCR
Email me when Lifecore Biomedical, Inc. \de\ files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.